GlassScriptPhysician profile
Jaber A Khan
NPI 1205857182
$11,426.56
in general payments reported to CMS, 2019-2025
69 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $1,776 · 2021: $2,394 · 2022: $1,593 · 2023: $1,529 · 2024: $1,448 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,368.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,623.00 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,321.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,086.01 | 2020-2025 | |
| Lilly USA, LLC | $953.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $656.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $629.47 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Preventric Diagnostics, INC. | $604.90 | 2021 | |
| Amgen INC. | $503.61 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $396.86 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $281.02 | 2019-2025 | Verquvo, Vaxneuvance, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $242.69 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $170.84 | 2023-2025 | Rexulti |
| Esperion Therapeutics, INC. | $162.76 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $160.04 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $157.28 | 2019-2021 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaber Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.